Bedside Snapshot
  • Core dose: IV bolus 0.5–1 mg slow IV push, may repeat every 2–3 h (max 10 mg/day); continuous infusion 0.5–2 mg/h after bolus; oral 0.5–2 mg once daily
  • Onset/duration: IV onset 2–3 min, peak ~5 min; oral onset 30–60 min; duration 4–6 hours; half-life ~1–1.5 h
  • Key danger: Profound diuresis → hypokalemia, hypomagnesemia, hypotension, dehydration; ototoxicity (usually reversible); absolutely avoid in anuria or severe uncorrected electrolyte depletion
  • Special: Loop diuretic ~40× more potent than furosemide (1 mg bumetanide ≈ 40 mg furosemide); inhibits NKCC2 in loop of Henle; promotes K⁺, Mg²⁺, Ca²⁺ loss; alternative when furosemide allergy/resistance
Brand & Generic Names
  • Generic Name: Bumetanide
  • Brand Names: Bumex (U.S.); Burinex (international markets)
Medication Class

Loop diuretic

Pharmacology

Mechanism of Action:

  • Inhibits the Na⁺–K⁺–2Cl⁻ cotransporter (NKCC2) in the thick ascending limb of the loop of Henle
  • Increases excretion of sodium, chloride, and water
  • Promotes urinary loss of potassium, calcium, and magnesium

Pharmacokinetics:

  • Absorption: Oral bioavailability 59–89%
  • Onset: IV 2–3 minutes; PO/IM 30–60 minutes
  • Peak: IV ~5 minutes; IM ~30 minutes; PO 1–2 hours
  • Duration: 4–6 hours
  • Distribution: Protein binding 94–96%; Volume of distribution 9–25 L (adults)
  • Metabolism: Partial hepatic metabolism to inactive conjugates and desbutyl metabolites
  • Elimination: Half-life ~1–1.5 hours in adults (prolonged in infants/neonates); primarily excreted in urine (~81%)
Indications
  • Primary indications: Edema due to heart failure, hepatic cirrhosis, or renal disease (including nephrotic syndrome)
  • Acute decompensated heart failure with volume overload (IV bolus or infusion)
  • Alternative when furosemide allergy or intolerance is present
  • Off-label uses: Adjunct in hypertension with volume overload or diuretic resistance when other loop diuretics are ineffective
Conditions Treated
  • Congestive heart failure (CHF) with volume overload
  • Acute decompensated heart failure (ADHF)
  • Hepatic cirrhosis with ascites
  • Renal disease with edema
  • Nephrotic syndrome
  • Hypertension with volume overload (off-label)
Dosing & Administration

Available Forms:

  • Tablets: 0.5 mg, 1 mg, 2 mg
  • Injection: 0.25 mg/mL (IV/IM)

Standard Adult Dosing:

Route Initial Dose Repeat Dosing Maximum
Oral 0.5–2 mg once May repeat in 4–5 hr for up to 2 doses 10 mg/day
IM 0.5–1 mg May repeat every 2–3 hr for up to 2 doses 10 mg/day
IV Bolus 0.5–1 mg slow IV push May repeat every 2–3 hr based on response 10 mg/day
IV Continuous Infusion 1–4 mg IV bolus initially Then 0.5–1 mg/hr infusion Typical ceiling 2 mg/hr
Dose Equivalence: 1 mg bumetanide ≈ 40 mg furosemide ≈ 20 mg torsemide (PO equivalents)
Continuous Infusion Titration: Titrate infusion to urine output and hemodynamics. Target urine output typically >150–200 mL/hr or individualized based on patient needs. Adjust infusion rate and consider adding thiazide synergy if inadequate response.
Contraindications

Absolute Contraindications:

  • Hypersensitivity to bumetanide or sulfonamides
  • Anuria (complete absence of urine production)
  • Severe uncorrected electrolyte depletion
  • Hepatic coma

Precautions:

  • Risk of profound diuresis and electrolyte loss
  • Monitor closely in renal or hepatic impairment
  • Use with caution in elderly patients
  • Ototoxicity risk increases with:
    • Rapid IV push
    • High doses
    • Renal dysfunction
    • Co-administration with aminoglycosides or other nephrotoxic/ototoxic agents
Warning: Ototoxicity risk is heightened with rapid IV administration, high doses, renal dysfunction, or concurrent use of aminoglycosides. Administer slowly and monitor hearing.
Adverse Effects

Common:

  • Hypokalemia (low potassium)
  • Hypomagnesemia (low magnesium)
  • Hyponatremia (low sodium)
  • Metabolic alkalosis
  • Hypocalcemia (low calcium)
  • Hyperuricemia (elevated uric acid)
  • Hyperglycemia (elevated blood glucose)
  • Hypotension
  • Dizziness or muscle cramps

Serious:

  • Ototoxicity (usually reversible, but can be permanent)
  • Severe volume depletion
  • Acute kidney injury (AKI) or azotemia
  • Severe dermatologic reactions (e.g., Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN])
  • Blood dyscrasias (rare)
Drug Interactions
  • Aminoglycosides (gentamicin, tobramycin, amikacin): Additive ototoxicity and nephrotoxicity—avoid or monitor closely
  • NSAIDs: May blunt diuretic response by reducing renal prostaglandins; monitor efficacy and renal function
  • ACE inhibitors / ARBs / other antihypertensives: Additive hypotension and AKI risk when combined in volume-depleted states
  • Lithium: Loop diuretics can increase lithium levels and toxicity—generally avoid or monitor lithium levels closely
  • Digoxin: Hypokalemia from loop diuretics increases digoxin toxicity risk—maintain potassium and magnesium levels
  • Other diuretics (thiazides, metolazone): Synergistic natriuresis—use for diuretic resistance with careful electrolyte monitoring
Aminoglycoside Warning: Concurrent use of aminoglycosides with bumetanide significantly increases risk of ototoxicity and nephrotoxicity. Avoid combination when possible or monitor closely with therapeutic drug levels.
Monitoring

Clinical Monitoring:

  • Strict intake and output (I/O)
  • Daily weights
  • Edema assessment and lung examination
  • Blood pressure and perfusion status
  • Hearing changes (especially with rapid IV dosing, renal dysfunction, or aminoglycoside co-administration)

Laboratory Monitoring:

  • Serum electrolytes—K⁺, Mg²⁺, Na⁺, bicarbonate
  • Renal function (BUN/Creatinine)
  • Uric acid
  • Glucose

Continuous Infusion Monitoring:

  • Urine output targets (e.g., >150–200 mL/hr or individualized)
  • Adjust infusion rate based on response
  • Add thiazide synergy if inadequate response
References
  • Medscape. (2025). Bumetanide (Bumex, Burinex) monograph. Retrieved November 11, 2025, from https://reference.medscape.com/drug/bumex-burinex-bumetanide-342421
  • U.S. Food and Drug Administration. (2024). Bumex (bumetanide) [Prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018225Orig1s029lbl.pdf
  • Martin, S. J., & Dasta, J. F. (2006). Pharmacologic management of acute heart failure. In Critical Care Clinics (Vol. 22, No. 6). Elsevier.
Clinical Pearls
Better Oral Bioavailability: Bumetanide has more predictable oral bioavailability (59–89%) compared to furosemide (10–90%). This makes it particularly helpful when gut edema impairs furosemide absorption in heart failure patients.
Continuous Infusion Strategy: Consider continuous infusion after a bolus to overcome diuretic resistance and reduce ototoxic peak concentrations. This provides more consistent diuresis with fewer adverse effects.
Dose Equivalence: Remember the 40:1 ratio—1 mg bumetanide ≈ 40 mg furosemide. Avoid exceeding practical ceiling doses; instead, add thiazide synergy (e.g., metolazone) for diuretic resistance.
"Sulfa" Allergy: Cross-reactivity with loop diuretics in sulfa allergy is uncommon but possible. If true sulfonamide allergy exists and cross-reactivity is a concern, ethacrynic acid is a non-sulfonamide loop diuretic alternative.
Cirrhosis Caution: In patients with cirrhosis, avoid over-diuresis as it can precipitate hepatic encephalopathy and acute kidney injury. Consider spironolactone as the primary diuretic for ascites management in cirrhotic patients.
Electrolyte Vigilance: Loop diuretics cause significant potassium and magnesium wasting. Monitor and replete aggressively, especially in patients on digoxin where hypokalemia increases toxicity risk.
Diuretic Resistance Strategy: When patients don't respond to adequate loop diuretic doses, add sequential nephron blockade with a thiazide (metolazone 2.5–5 mg PO daily). This blocks distal tubule compensation and provides synergistic diuresis. Monitor electrolytes closely.
Back to Medication Index
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.